OR WAIT null SECS
GlaxoSmithKline opened a new vaccines R&D center in Rockville, MD creating up to 200 new jobs.
On Dec. 13, 2016, GlaxoSmithKline (GSK) announced the inauguration of the company’s new global vaccines R&D center in Rockville, MD. The company said the new facility will create approximately 200 new jobs, and the company will invest more than $50 million in the next two years to continue to develop the site.
The facility will house 12 vaccine development programs including projects supporting the company’s candidate shingles vaccine, programs for respiratory syncytial virus, Group B Streptococcus, and dengue fever. The Rockville site becomes one of three global vaccines R&D centers for GSK including centers in Rixensart, Belgium, and in Siena, Italy. Rockville is also the location of GSK’s proposed biopreparedness organization (BPO), a dedicated, permanent organization using a no profit/no loss model that will design and develop new vaccines against emerging viruses, bacteria, and other pathogens that potentially pose a threat to global public health.